AnalystsInsight

Tycho Peterson (Jefferies): Analyst Track Record and Price‑Target Accuracy

How often Tycho Peterson’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 785 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

Key takeaways

  • Tycho Peterson ranks #794 of 1,121 analysts in Exent’s scoring (4.7★).
  • 55.8% of price targets were reached over 7 years, versus 53.6% for the average analyst.
  • Median time to reach a target: 75 days; 44.8% of calls were up 12 months later.
  • Most‑covered stocks: QGEN, TMO, BRKR, DHR.
  • Free on Exent: Tycho Peterson’s full record, with ratings 3 days after publication.

Tycho Peterson’s track record at a glance

Tycho Peterson of Jefferies ranks #794 of the 1,121 analysts Exent scores, with a 4.7★ rating and a focus on healthcare. Over a 7‑year lookback, 55.8% of Tycho’s price targets were reached, 2.2 points above the 53.6% average across all analysts.

MetricTycho PetersonAll analysts
Price‑target hit rate55.8%53.6%
Median days to hit target75 days91 days
Calls up after 12 months44.8%64.6%
Median 12‑month return of calls−3.5%+13.4%
Hit rate, last 2 years56.0%—
Average worst drop after a call−26.4%—
Ratings in the sample785—
Stocks covered55—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetTycho Peterson
Under 30 days22.2%
30–90 days36.2%
90–180 days18.5%
Over 180 days23.0%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Tycho Peterson covers most

StockRatings in the sample
QGEN41
TMO35
BRKR29
DHR26
WAT26
WGS21
A20
AVTR20

In the past year Tycho’s ratings were 84% Buy, 13% Hold and 4% Sell.

Tycho Peterson’s latest ratings

DateStockActionRatingPrice target
Oct 7, 2026EWInitiated Coverage: BuyBuy$110.00
Sep 18, 2026DHRReiterated: BuyBuy$210.00
Sep 11, 2026AReiterated: HoldHold$155.00
Sep 2, 2026AReiterated: HoldHold$155.00
Aug 17, 2026FRNMInitiated Coverage: BuyBuy$17.00
Aug 17, 2026NTRAReiterated: BuyBuy$330.00
Aug 7, 2026TXGReiterated: BuyBuy$53.00
Aug 6, 2026QGENReiterated: BuyBuy$0.00
Aug 4, 2026BME-BBVAReiterated: BuyBuy$27.50
Jul 31, 2026MTDReiterated: BuyBuy$1580.00
Jul 30, 2026BME-BBVAReiterated: BuyBuy$27.00
Jul 29, 2026AVTRUpgraded: HoldHold$13.00
  • Oct 7, 2026
    Stock
    EW
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $110.00
  • Sep 18, 2026
    Stock
    DHR
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $210.00
  • Sep 11, 2026
    Stock
    A
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $155.00
  • Sep 2, 2026
    Stock
    A
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $155.00
  • Aug 17, 2026
    Stock
    FRNM
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $17.00
  • Aug 17, 2026
    Stock
    NTRA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $330.00
  • Aug 7, 2026
    Stock
    TXG
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $53.00
  • Aug 6, 2026
    Stock
    QGEN
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 4, 2026
    Stock
    BME-BBVA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $27.50
  • Jul 31, 2026
    Stock
    MTD
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $1580.00
  • Jul 30, 2026
    Stock
    BME-BBVA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $27.00
  • Jul 29, 2026
    Stock
    AVTR
    Action
    Upgraded: Hold
    Rating
    Hold
    Price target
    $13.00

Tycho’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Oct 20, 2026; ranking updated Oct 21, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Tycho Peterson’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Tycho Peterson ranks #794 of 1,121 with a 4.7★ rating. 55.8% of price targets were reached over a 7-year lookback (all analysts: 53.6%), and 44.8% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Tycho Peterson’s success rate is 57.5% by the ranking source and 55.8% by Exent’s price-target hit-rate backtest, with a median of 75 days to reach a target.

Tycho Peterson (Jefferies) covers 55 stocks, mostly in healthcare. The most frequently rated are QGEN, TMO, BRKR, DHR, WAT.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.